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1Chapter
Cognitive Function and Quality of 
Life of Muscular Dystrophy
Yukihiko Ueda
Abstract
Duchenne muscular dystrophy and myotonic dystrophy are genetic, progres-
sive muscle diseases. These muscular dystrophies, which are currently incurable, 
cause muscle wasting or muscle weakness and decrease patients’ quality of life. In 
addition to muscular impairments, cognitive impairments are also reported in both 
Duchenne muscular dystrophy and myotonic dystrophy. Cognitive impairments in 
each type of muscular dystrophy are different and closely related to psychosocial 
variables and the quality of life of the patients. We reviewed the features of cogni-
tive functions in each type of muscular dystrophy and their correlations with 
the quality of life of patients. Based on the findings, we have suggested effective 
interventions for improving the quality of life of muscular dystrophy patients.
Keywords: Duchenne muscular dystrophy, myotonic dystrophy, quality of life, 
cognitive function
1. Introduction
Muscular dystrophy is a genetic, progressive disease of the muscles with several 
clinical forms, all of which have an early onset and are incurable with current 
medical technology. These diseases severely decrease motor functions and make 
it difficult to live an independent social life or engage in an occupation. In this 
decade, the life span of muscular dystrophy patients has improved considerably 
as a result of improvements to ventilators. Therefore, it has become necessary 
to help patients maintain their quality of life (QOL) throughout the life span. 
Furthermore, muscular dystrophy causes not only physical impairments but also 
cognitive impairments [1]. Such cognitive impairments are associated with difficul-
ties in communicating with medical workers and family members and also affect 
medical compliance and the QOL.
2. QOL of patients with muscular dystrophy
Muscular dystrophy has an early onset, and thereafter body functions decrease 
progressively beginning with a decrease in motor functions that require the use of 
a wheelchair to maintain mobility and a decrease in the breathing function that 
require a ventilator to maintain breathing, which makes the patients bedridden. 
As a result, the patients’ behavior repertoire becomes severely restricted, and 
they require considerable assistance. Netterlund et al. investigated activities of 
daily living (ADL) and the QOL of 45 people (mean age 44 years) with muscular 
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dystrophy [2] and reported that all the sampled patients were living at home. The 
QOL was assessed by the Sickness Impact Scale (SIP) and the Psychosocial Well-
Being Questionnaire, which indicated that their disability and dependence on 
others increased, whereas ADL decreased during the previous 5 years. Moreover, 
the patients’ QOL and life satisfaction also decreased. Boström and Ahlström 
investigated 46 people with muscular dystrophy through interviews using a quali-
tative research approach for 10 years [3]. They reported that nearly all muscular 
dystrophy patients had decreasing functions such as limited mobility, increasing 
fatigue, and feebleness, accompanied by psychological distress. Moreover, if there is 
a difficulty in securing assistance for patients to continue living in their homes, they 
must live in recuperation wards.
Ueda et al. [4] investigated the QOL of 50 inpatients with muscular dystro-
phy. The QOL was assessed by the World Health Organization-Quality of Life 
26 (WHO-26). Results indicated that the mean QOL score (SD) of patients with 
muscular dystrophy was 2.96 (0.34), which was significantly lower than the general 
Japanese population (mean 3.75) or patients with cancer (mean 3.3). The results of 
the comparison between patients’ conditions indicated that those who could move 
by using a wheelchair had higher QOL scores than those who were bedridden. The 
QOL score of patients that had throat surgery was higher than those who had no 
surgery. The comparison between clinical types indicated that the QOL in myotonic 
dystrophy was significantly lower than limb girdle-type muscular dystrophy or 
Fukuyama-type congenital muscular dystrophy. They also investigated factors that 
could affect the QOL of patients with muscular dystrophy, including age,  
gender, clinical type, duration of the diseases, throat surgery, duration from throat 
surgery, functional independence (Barthel Index), use of a ventilator, use of a 
wheelchair, use of a computer, the frequency of family visits, and participation 
in activities. The results of categorical regression analysis (R2 = 0.671, R2 = 0.400, 
F = 2.479, P < 0.05) showed that only the use of a computer influenced the QOL 
(β = 0.598). These results suggest that using a computer could be an effective method 
of maintaining or improving the QOL of muscular dystrophy inpatients, with dete-
riorated body functions and limited activities due to the progression of the disease.
3. Profile of cognitive functions in Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a genetic disease of the muscles caused 
by deficits in the dystrophin-glycoprotein complex (DGC). The loss of dystrophin 
is associated with a complex set of physiological and anatomical adaptations that 
are known contributors to the cognitive deficits observed in patients with DMD and 
related disorders. Some studies have indicated disordered CNS architecture, abnor-
malities in dendrites, and loss of neurons in boys with DMD [5]. These boys show 
EEG abnormalities [5], and the prevalence of epilepsy is higher in DMD (6.3%) 
than the general population [6]. Studies of CT [7] and MRI [8] have indicated brain 
atrophy in patients with DMD. These studies suggest that functional and morpho-
logical abnormalities are affected by the absence of dystrophins.
Several studies have assessed the intellectual functioning of boys with DMD 
and reported mean IQs that are approximately one standard deviation lower than 
the general population [9–12]. Also, boys with DMD have lower verbal IQs (VIQ ) 
than performance IQs (PIQ ) [10, 13–16]. Furthermore, Hinton et al. [17] indi-
cated that boys with DMD did poorly on Story Recall, Digit Span, and Auditory 
Comprehension compared to unaffected siblings. They concluded that verbal 
working memory was impaired selectively. Moreover, sequential processing ability 
is more impaired than simultaneous processing ability in boys with DMD [14, 18].
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Cotton [19] reported that the boys with DMD had a mean full-scale IQ (FIQ ) 
and a PIQ score of approximately 80 based on a meta-analysis of 1224 boys with 
DMD. However, the mean VIQ scores improved with age, particularly in the verbal 
subscales: Information, Similarities, Arithmetic, Comprehension, and Digit Span. 
Moreover, there were less deficits in older age groups in abilities of logical verbal 
abstract reasoning, language development, and arithmetic. They suggested the 
need to adopt more specific and directed neuropsychological assessments to further 
delineate age-related cognitive changes in DMD populations [19].
3.1 Cognitive functions in adults with DMD
Ueda et al. [20] conducted a study using a wide range of neuropsychological 
assessment instruments to investigate whether the cognitive weaknesses remain in 
adult patients with DMD.
Fifteen inpatients and outpatients with DMD (mean age = 30.4 years, age 
range = 19–44 years) participated in the study. Twenty-four subscales of the 
Wechsler Adult Intelligence Scale-III (WAIS-III), the Clinical Assessment for 
Attention (CAT) [21], and the Wechsler Memory Scale (WMS-R) were used for the 
assessment. The assessment instruments were:
• Ten WAIS-III subscales: (1) Picture Completion, (2) Vocabulary, (3) Similarities, 
(4) Arithmetic, (5) Matrix Reasoning, (6) Information, (7) Comprehension, (8) 
Symbol Search, (9) Letter-Number Sequencing, and (10) Digit Span
• Seven subscales of CAT: (11) Auditory Detection, (12) Symbol Digit 
Modalities, (13) Memory Updating (3 span), (14) Memory Updating (4 span), 
(15) Paced Auditory Serial Addition Test (PASAT; 2 sec.), (16) PASAT (1 sec.), 
and (17) Position Stroop
• Seven subscales of WMS-R: (18) Logical Memory, (19) Visual Paired 
Association, (20) Verbal Paired Associate, (21) Figural Memory, (22) Delayed 
Logical Memory, (23) Delayed Visual Paired Association, and (24) Delayed 
Verbal Paired Associates
All assessment instruments were standardized for use in Japan. Therefore, the 
Z test was used to compare the scores of DMD patients on the 24 subscales with the 
normal population.
The mean and SD of WAIS-III in DMD adults patients (Figure 1), Picture 
Completion (M = 6.20, SD = 2.86), Arithmetic (M = 5.80, SD = 1.97), Matrix Reasoning 
(M = 7.47, SD = 3.74), Symbol Search (M = 6.20, SD = 3.84), Letter-Number Sequencing 
(M = 6.97, SD = 4.64), and Digit Span (M = 7.33, SD = 2.23) were significantly defi-
cient (p < . 01) compared to the normal population (M = 10, SD = 3). However, there 
were no significant differences in Vocabulary (M = 8.80, SD = 3.28), Similarities 
(M = 8.80, SD = 4.31), Information (M = 8.93, SD = 3.08), and Comprehension 
(M = 9.33, SD = 4.61). The mean FIQ of adult patients with DMD was 87.4 (SD = 15.96, 
range = 61–109), which was estimated by dyadic short forms of WAIS-III [22, 23].
On the CAT, they were significantly deficient in all subscales (Figure 2): Symbol 
Digit Modalities (M = 42.5, SD = 12.5), Auditory Detection (M = 84.2, SD = 18.8), 
Memory Updating 3 span (M = 79.2, SD = 25.9), Memory Updating (4 span)  
(M = 51.4, SD = 30.4), PASAT (2 sec.) (M = 37.2, SD = 30.5), PASAT(1 sec.) 
(M = 17.4, SD = 16.1), and Position Stroop (M = 97.1, SD = 3.3). In addition, the total 
Response Time for Position Stroop of patients group (M = 163.0, SD = 75.5) was 
significantly longer than the normal population.
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On the WMS-R, Logical Memory (M = 18.3, SD = 13.1) and Delayed Logical 
Memory (M = 15.8, SD = 11.7, Z = 2.495, p < .01) were significantly lower. However, 
there were no significant differences between patient group and normal population 
in other subscales: Visual Paired Association (M = 14.6, SD = 4.1), Verbal Paired 
Associates (M = 19.3, SD = 5.4), Figural Memory (M = 7.6, SD = 2.0), Delayed Visual 
Paired Association (M = 5.7, SD = 0.8), and Delayed Verbal Paired Association 
(M = 7.5, SD = 1.1) (Figure 3).
These results indicate that specific cognitive functions of adults with DMD are 
deficient compared to the normal population. In particular, the ability to sequen-
tially process auditory information was reduced in attention and memory. On the 
other hand, cognitive abilities that do not require sequential processing were not 
impaired, suggesting that adults with DMD remain relatively weak in sequential 
auditory information processing. Moreover, tests of visual information processing 
showed impairments. These findings suggest that sequential visual information 
Figure 1. 
Comparison between DMD sample (N = 15) and normal population for WAIS-III. Means and SDs for 
standard scores are shown. The mean and SD for the normal population are 10 and 3. **p < .01. Ueda et al. [4].
Figure 2. 
Comparison between DMD sample (N = 15) and normal population for CAT. Means and SDs for percentage 
of correct answers are shown. **p < .01. Ueda et al. [4].
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processing involving alterations of attention and processing speeds were weak in 
adult patients with DMD. The weaknesses of cognitive functions were maintained 
without improvement in adults with DMD. It suggests that these deficits are not 
caused by environmental factors but represent organic impairments.
Taylor et al. [24] reported differences in neuropsychological profiles of DMD 
patients and then postulated that these differences are caused by the affected num-
ber and type of CNS-expressed isoforms. The site of DMD mutation and the extent 
of the cognitive deficits are related to each other distinctly. The best model for this 
phenomenon was that mutations affecting exons 45 to 50 are mainly mutations of 
coding exons. This effect is restricted to Dp260 and Dp427. In the case of mutations 
that affected the coding regions of the CNS expressing isoforms Dp140pc and Dp71 
are clustered together, there was a significant difference in the degree of cognitive 
disability. Mutations affecting the Dp140 isoforms affected FIQ less than muta-
tions affecting the Dp140 promoter or protein-coding regions [24]. Nevertheless, 
the relationship between these isoforms and the ability of sequential information 
processing has not been clarified. Further research is needed to explore the mecha-
nisms underlining cognitive deficits associated with DGC.
Over the past few decades, the prognosis of DMD patients has shown remark-
able improvement; however, the improvement of their quality of life still remains 
as an important task. Compared with ADHD [25], autistic spectrum disorders, and 
obsessive–compulsive disorders [25, 26], cognitive problems of DMD patients have 
been discussed. Particularly, the poor facial recognition of DMD patients [27] might 
have a negative influence on their QOL. A better evaluation of cognitive deficits in 
DMD patients could improve their relationship with care staff, thereby contributing 
to better care and improving the QOL.
4. Cognitive functions of myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is a chronic progressive multi-system disorder 
with autosomal dominant inheritance. This disorder is caused by a cytosine-
thymine-guanine (CTG) repeat expansion in the protein kinase (DMPK) gene [28], 
Figure 3. 
Comparison between DMD sample (N = 15) and normal population for WMS-R. Raw means and SDs are 
shown. *p < .05, **p < .01. Ueda et al. [4].
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resulting in cognitive and psychiatric dysfunctions that have a significant impact on 
the QOL [29, 30].
Okkersen et al. [31], based on a systematic review and meta-analysis, dem-
onstrated that DM1 patients have significant deficits in all cognitive domains 
compared to controls. Effect sizes were large (−.76–−1.01) for global cognition, 
intelligence, visual memory, visuospatial perception, visuoconstruction, psy-
chomotor speed, and social cognition. Moreover, small to medium effect sizes 
(−.33–−.66) were observed for language, executive functioning, overall and verbal 
memory, as well as attention.
A few studies have examined the relationship between cognitive impairment 
and the QOL [30, 32, 33]. However, the majority of these studies did not take all the 
Table 1. 
Cognitive function of patients with DM1 (Fujino et al. [34]).
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domains of cognition into consideration, and they used QOL measures insensitive 
to specific issues related to DM1.
4.1 Assessment of cognitive function of DM1
Fujino et al. [34] conducted a study of the affected cognitive domains and 
evaluated the relationship between cognitive functions, psychological factors, 
and the QOL. Participants (N = 60) were recruited from five hospitals of National 
Hospital Organization in Japan. The general cognitive functions of the participants 
were evaluated with the Japanese version of the Mini-Mental State Examination 
(MMSE), and the estimated IQ was calculated from two subsets (Picture 
Completion and Information) of WAIS-III. Abstract reasoning was evaluated by 
using the Similarities subset and the Visual Perceptions Test for Agnosia (VTPA) 
Story Telling subset [35] in WAIS-III. Attention and working memory were evalu-
ated with CAT subsets (Digit Span [forward, backward], Tapping Span [forward, 
backward], Auditory Detection task, Memory Updating 3, and PASAT-2. Executive 
function was evaluated with the Wisconsin Card Sorting Test (WCST), the Frontal 
Assessment Battery (FAB), the Trail Making Test (TMT)-B, the CAT Position 
Stroop test, and the semantic and phonemic fluency test. For the assessment of 
processing speed, TMT-A and 2 CAT subtests (Visual Cancelation task and Symbol 
Digit Modalities test) were used. For the evaluation of visuoconstructive ability, the 
WAIS-III Block Design and VPTA subtests (Copying Figures and Flowers, Bisection 
of Lines) were used. The CAT and VPTA are cognitive functional test batteries, 
which were developed by the Japan Society for Higher Brain Dysfunction.
As in psychological functioning, the five specific domains were assessed: apathy, 
depression, excessive daytime sleepiness, fatigue, and social responsiveness. The 
evaluation tools were Apathy Scale [36], Patients Health Questionnaire-9 (PHQ-9) 
[37], Epworth Sleepiness Scale (ESS) [38], Multidimensional Fatigue Inventory 
(MFI) [39], and Social Responsiveness Scale (SRS) [40]. The QOL was estimated 
with the Muscular Dystrophy Quality of Life Scale (MDQoL) [41] that was devel-
oped for Japanese patients with muscular dystrophies including DM1. This scale 
consists of 10 subscales: Psychological Stability, ADL, Environment, Hope, Activity, 
Health Relationships, Family, Sexuality, Breathing, and Defecation.
Table 2. 
Psychological variables and QOL of patients with DM1 (Fujino et al. [34]).
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4.2 Cognitive impairments and QOL of DM1
The mean age of the 60 participants with DM1 (35 men and 25 women) was 47.1 
(SD = 10.8), and the mean age at the onset of DM1 was 29.0 (SD = 13.2). Moreover, 
the mean duration of illness was 17.2 years (SD = 11.4). Also, the mean number of 
CTG repeats was 1132.2 (SD = 1025.2).
The results indicated that most cognitive functions of DM1 patients were 
lower than the general population (Table 1). In particular, more than half of the 
patients scored 2 SD lower than the general population for attention and working 
Table 3. 
Correlations between cognitive function and QOL (Fujino et al. [34]).
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memory (Auditory Detection task, 67% [hit], 60% [correct]), executive func-
tion (Position Stroop test, 79%), processing speed (Visual Cancelation task, 91%, 
Symbol Digit Modalities test, 54%), and visuoconstructive ability (Block Design, 
64%). Although patients were markedly impaired on tasks that assessed complex 
attentional functions (PASAT-2 and Memory Updating 3), they were not severely 
affected on those assessing simple attentional functions (Digit Span [forward] 
and Tapping Span [forward]. Certain patients scored 2 SD higher than the general 
population on psychological factors including apathy (22%), depression (23%), 
and fatigue (15%) (Table 2).
Factor analysis categorized MDQoL results into Psychosocial relationship factor 
and Physical functioning and Health factor. The Psychosocial relationship factor was 
associated with Digit Span (forward, r = 0.39), Tapping Span (forward, r = 0.40), 
TMT-A (r = −0.38), and Visual Cancelation task (r = −0.48) (Table 3). Additionally, 
the Psychosocial relationship factor was negatively associated with apathy 
(r = −0.37), depression (r = −0.52), and fatigue (r = −0.42). Physical Functioning 
and Health factor was negatively associated with depression (r = −0.66) and fatigue 
(r = −0.55). Apathy was associated with the FAB (r = −0.47), Visual Cancelation 
(r = o.46), and Auditory Detection task (r = −0.44) (Table 4).
These results demonstrated that patients with DM1 have specific cognitive 
impairments including executive dysfunctions, processing speed impairments, 
attentional problems, and visuoconstructive problems. Improved cognitive abili-
ties in attention and working memory, as well as processing speed, were associated 
with higher QOL, whereas higher apathy, depression, and fatigue were associated 
with lower QOL. It is possible that apathy mediates the influence of cognitive 
functions on the QOL, which suggest that the reduction of apathy might lead to 
better cognitive performance or vice versa [42]. Cognitive assessment can provide 
useful information for patients, allowing them to plan support in their daily lives. 
Cognitive interventions might also contribute to improving the QOL of patients 
with DM1 because neuropsychological rehabilitation and cognitive remediation 
have been effective in other neurological conditions [43–45].
5. Psychopathological features and personality of DM1 patients
Some studies pointed that depression and fatigue predict psychological and 
physical QOL in patients with muscular diseases [46, 47]. Additionally, apa-
thy could promote social inhibition and avoidance of social interactions [48]. 
All of them, in conjunction with each other, lead to the deterioration of the 
Table 4. 
Correlation between psychological variables and QOL (Fujino et al. [34]).
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QOL. Therefore, the psychological interventions for DM1 should incorporate these 
factors as potential targets for improving patients’ QOL.
Minier et al. [49] conducted a systematic literature review of psychopathological 
features in DM1 and reported that patients with DM1 present mild psychopatholog-
ical problems, such as interpersonal difficulties, lack of interest, dysphoria, concern 
about bodily functioning, and hypersensibility. However, they do not present more 
psychiatric disorders than the general population, except for personality disorders 
and depression. Moreover, avoidant personality disorder was the most common of 
several personality disorders among DM1 patients.
5.1 Lack of awareness about the illness
In clinical practice, DM1 patients commonly showed less awareness of the 
disease distress and its progression. This is named anosognosia or lack of awareness, 
which can lead to misattributions of symptoms, delay of diagnostic procedures, and 
low compliance with treatment. The lack of awareness about their illness often is 
observed in individuals with brain diseases and neurodegenerative disorders, such 
as Alzheimer’s diseases and acquired brain injury. In these disorders, the lack of 
awareness can be a direct consequence of the underlying pathological process [50]. 
Research on brain injuries suggests that the prefrontal cortex plays a crucial role in 
maintaining awareness [51].
Baldanzi et al. [52] conducted a study to estimate the prevalence of disease 
awareness in 65 adult patients with DM1. The degree of awareness was evaluated 
by comparing motor impairments using MIRS, patients’ complaints about their 
symptoms, and by comparing INQOL between caregivers. The results indicated 
that 51.6% of patients were unaware of the disease, and the lack of awareness was 
most prominent in Independence (52.4%) and Social Relationship (47.6%) domains. 
Moreover, the lack of awareness was significantly related to failures in cognitive test 
performance, specifically in the domains of visuospatial memory, cognitive flexibil-
ity, and conceptualization. Baldanzi et al. suggested that gaining a better under-
standing of anosognosia would be useful for the medical management of patients 
with DM1 and for providing guidance for occupational and social interventions.
6. Interventions
DM1 leads to substantial physical impairments, which in combination with 
the neuropsychological effects of the condition results in severely restricted social 
participation. However, there is little evidence for the efficacy of rehabilitative 
approaches designed to improve health status. Previous studies have demonstrated 
that fatigue is a highly prevalent, debilitating symptom of DM1 [53, 54], and cogni-
tive behavioral therapy reduces fatigue and increases objective activity, as well as 
social participation in patients with facioscapulohumeral muscular disease [55]. 
Therefore, Okkersen et al. [56] conducted a large randomized trial to determine 
whether cognitive behavioral therapy plus optional graded exercise improved the 
health status of patients with DM1 compared to standard care alone.
6.1 Cognitive behavioral therapy for the patients with DM1
The study by Okkersen et al. [56] was a large-scale, multicenter, single-blind, 
randomized trial conducted at four neuromuscular referral centers located in 
France, Germany, Netherlands, and the UK, which was known as Observational 
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Prolonged Trial In Myotonic Dystrophy Type 1 to Improve Quality of Life-
Standards, a Target Identification Collaboration (OPTIMISTIC). Participants 
(N = 255) were aged 18 years and older with a confirmed genetic diagnosis of 
DM1, who were severely fatigued (CIS-fatigue scale, score ≧35) but able to walk 
independently. They were randomly assigned to either cognitive behavioral therapy 
plus standard care and optional graded exercise (n = 128) or standard care alone 
(n = 127). Cognitive behavioral therapy focused on addressing the reduced initia-
tive in the patients, increasing physical activity, optimizing social interactions, 
regulating sleep–wake patterns, coping with pain, and beliefs about fatigue and 
DM1. Cognitive behavioral therapy was delivered over a 10-month period in 10–14 
sessions based on a manual, by therapists that had extensive training. It was possible 
to include a graded exercise module that was individually tailored and incorporated 
moderate-intensity exercises such as walking, cycling, jogging, or dancing for a 
minimum of 30 minutes, three times a week.
The active-c score of participants in cognitive behavioral therapy increased 
from a mean (SD) of 61.22 (17.35) at baseline to 63.92 (17.41) at the 10th month. 
However, the score decreased from 63.00 (17.35) to 60.79 (18.49) in the standard 
care group. The mean difference between the groups was 3.27 and significant 
(p = 0.007). As secondary outcomes, the cognitive behavior therapy group showed 
significant differences in the 6-minute walk test, the fatigue and daytime sleepiness 
scales, CIS-fatigue, and daily activity levels. Moreover, both groups had decreased 
scores in the myotonic dystrophy health index and INQOL. However, there was no 
significant difference between the groups. Also, there were no changes or no dif-
ferences between the groups on the apathy scale, Stroop-color-word interference, 
accelerometry for the least active 5 hours, or the Beck Depression Inventory. Based 
on these results, Okkersen et al. [56] emphasized that cognitive behavioral therapy 
could increase the capacity for activity and social participation in severely fatigued 
patients with DM1. This study showed that cognitive behavioral therapy could be 
one effective intervention for improving the health status of patients with DM1.
7. Conclusion
Cognitive impairments are observed in patients with DMD and DM1. These 
impairments are caused by gene mutations, especially by CNS-expressed isoforms. 
These impairments, however, do not encompass every aspect of their intellectual 
ability. Patients with DMD show deficits in sequential information processing and 
alterations of attention and processing speed. Moreover, patients with DM1 have 
weaknesses in executive function, processing speed, attention, and visuocon-
structive abilities. These cognitive impairments are related to their psychosocial 
characteristics, social participation, and the QOL. Especially, apathy, depression, 
and fatigue are the key factors that deteriorate the QOL of patients with DM1. It is 
suggested that precisely targeted cognitive assessments and cognitive intervention 
are necessary to provide them with better care and improve their QOL.
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